Literature DB >> 27990603

Sinonasal characteristics and quality of life by SNOT-22 in adult patients with cystic fibrosis.

Suzie Hyeona Kang1,2, Camila Degen Meotti3, Karine Bombardelli3, Otávio Bejzman Piltcher3,4, Paulo de Tarso Roth Dalcin5,6.   

Abstract

The prevalence of chronic sinus disease in cystic fibrosis (CF) has gradually increased. Sinonasal involvement may have influence on pulmonary exacerbations and can have a negative impact on the quality of life. To evaluate nasal characteristics and quality of life in adult patients with CF; to establish an association and determine the predictors in SNOT-22 questionnaire. Cross- sectional study with prospective data collection was performed to evaluate adult CF patients. Patients underwent clinical evaluation, lung function tests, nasal endoscopy, and paranasal sinuses CT scan. All the patients answered the SNOT-22 questionnaire.
RESULTS: A total of 91 patients were allocated, of which, 45.1% were male. Patients were divided into three groups by SNOT-22. A high average age, late age of diagnosis, rhinitis symptoms, and clinical criteria for rhinosinusitis were observed more frequently in patients with high SNOT-22 scores (p < 0.05). Overall, 84.6% patients had abnormal CT findings, with aplasia/hypoplasia of the sphenoid sinus being the most common finding. In multiple regression model, age, female gender, and Pseudomonas aeruginosa in the sputum were associated with high SNOT-22 scores in the nasal domain. Hyposmia and lack of medial bulging of lateral nasal wall were variables associated with high SNOT-22 scores in the quality of life domain. In total score, there was a positive association with age and the presence of P. aeruginosa in sputum. Despite high prevalence of abnormal tomographic findings, patients reported mild intensity of sinonasal symptoms. Advanced age and the presence of P. aeruginosa were associated with higher SNOT-22 scores.

Entities:  

Keywords:  Cystic fibrosis; Nasal polyposis; Quality of life; Rhinosinusitis; SNOT-22

Mesh:

Year:  2016        PMID: 27990603     DOI: 10.1007/s00405-016-4426-2

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  52 in total

1.  Evaluation of chronic rhinosinusitis management using the SNOT-22 in adult cystic fibrosis patients.

Authors:  V Savastano; S Bertin; T Vittori; C Tripodi; G Magliulo
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014       Impact factor: 3.507

2.  Correlation between preoperative symptom scores, quality-of-life questionnaires, and staging with computed tomography in patients with chronic rhinosinusitis.

Authors:  David A M Wabnitz; Salil Nair; P J Wormald
Journal:  Am J Rhinol       Date:  2005 Jan-Feb

3.  EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists.

Authors:  Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald
Journal:  Rhinology       Date:  2012-03       Impact factor: 3.681

4.  A multi-centre study on quality of life and absenteeism in patients with CRS referred for endoscopic surgery.

Authors:  P Sahlstrand-Johnson; B Ohlsson; C Von Buchwald; M Jannert; Marianne Ahlner-Elmqvist
Journal:  Rhinology       Date:  2011-10       Impact factor: 3.681

5.  Correlation between genotype and phenotype in patients with cystic fibrosis.

Authors: 
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

Review 6.  Paranasal sinus disease in patients with cystic fibrosis.

Authors:  G J Nishioka; P R Cook
Journal:  Otolaryngol Clin North Am       Date:  1996-02       Impact factor: 3.346

7.  Pathological changes of the lateral nasal wall in patients with cystic fibrosis (mucoviscidosis).

Authors:  P Brihaye; P A Clement; I Dab; B Desprechin
Journal:  Int J Pediatr Otorhinolaryngol       Date:  1994-01       Impact factor: 1.675

8.  Respiratory patterns in spirometric tests of adolescents and adults with cystic fibrosis.

Authors:  Bruna Ziegler; Paula Maria Eidt Rovedder; Paulo de Tarso Roth Dalcin; Sérgio Saldanha Menna-Barreto
Journal:  J Bras Pneumol       Date:  2009-09       Impact factor: 2.624

Review 9.  Chronic sinusitis: symptoms versus CT scan findings.

Authors:  Michael G Stewart; Romaine F Johnson
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2004-02       Impact factor: 2.064

10.  Expression of cyclooxygenase and lipoxygenase enzymes in sinonasal mucosa of patients with cystic fibrosis.

Authors:  Jonathan M Owens; Kenneth R Shroyer; Todd T Kingdom
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2008-08
View more
  4 in total

1.  Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis.

Authors:  Amanda L Stapleton; Adam J Kimple; Jennifer L Goralski; S Mehdi Nouraie; Barton F Branstetter; Amber D Shaffer; Joseph M Pilewski; Brent A Senior; Stella E Lee; Anna C Zemke
Journal:  J Cyst Fibros       Date:  2022-03-14       Impact factor: 5.527

2.  Outcomes of endoscopic sinus surgery in adult lung transplant patients with cystic fibrosis.

Authors:  Paolo Luparello; Maria S Lazio; Luca Voltolini; Beatrice Borchi; Giovanni Taccetti; Giandomenico Maggiore
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-01-28       Impact factor: 2.503

3.  TAS2R38 is a novel modifier gene in patients with cystic fibrosis.

Authors:  Alice Castaldo; Gustavo Cernera; Paola Iacotucci; Chiara Cimbalo; Monica Gelzo; Marika Comegna; Antonella Miriam Di Lullo; Antonella Tosco; Vincenzo Carnovale; Valeria Raia; Felice Amato
Journal:  Sci Rep       Date:  2020-04-02       Impact factor: 4.379

4.  A systematic review of patient-reported outcome measures (PROMs) in cystic fibrosis.

Authors:  Irushi Ratnayake; Susannah Ahern; Rasa Ruseckaite
Journal:  BMJ Open       Date:  2020-10-01       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.